Medicare Part D: Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier
DIANE Publishing, 2010 - 43 pages
The Centers for Medicare and Medicaid Serv. (CMS) allows Part D plans to utilize different tiers with different levels of cost sharing as a way of managing drug utilization and spending. One such tier, the specialty tier, is designed for high-cost drugs (HCD) whose prices exceed a certain threshold. Beneficiaries who use these drugs typically face higher out-of-pocket costs than those who use only lower-cost drugs. This report provides info. about HCD eligible for a specialty tier incl. spending under Medicare Part D; how different cost-sharing structures could be expected to affect beneficiary out-of-pocket costs; how negotiated drug prices could be expected to affect beneficiary out-of-pocket costs; and Part D plan sponsors ability to negotiate price concessions. Illus.
What people are saying - Write a review
We haven't found any reviews in the usual places.
$295 deductible 20 specialty tier–eligible 25 percent 33 percent coinsurance Adalimumab affect beneficiary out-of-pocket affect out-of-pocket costs Atazanavir beneficiaries reach beneficiaries taking beneficiary out-of-pocket costs billion Bosentan calendar catastrophic coverage threshold CMS data cost sharing coverage gap covered drugs Defined Standard Benefit different cost-sharing structures eligible drugs enrollment Erlotinib expected to affect formulary full subsidy LIS Gaucher disease Glatiramer acetate Gleevec high-cost drugs initial coverage period Interferon beta-1a Kaletra Lopinavir MA-PD and PDP Medicare Part D Medicare Prescription Drug mg tablet negotiate price concessions negotiated drug prices non-LIS beneficiaries out-of paid 15 percent partial subsidy LIS PDP plans percent of drug Plan paid plan sponsors pocket costs premium prescription drug plans prior authorization reach the catastrophic rheumatoid arthritis sample of 20 specialty tier specialty tier–eligible drugs spending on specialty sponsors we interviewed sponsors we surveyed subsidy LIS beneficiaries Teriparatide total drug costs Truvada utilization management practices Variations in Negotiated